Awards
Boehringer Ingelheim awards Proxygen with BI Innovation Prize
31 July 2020 —
The young biotech company Proxygen yesterday received the BI Innovation Prize for 12 months of free office and lab space in the new Start-Up Labs incubator at the Vienna BioCenter, as well as access to Boehringer Ingelheim’s expertise. Proxygen develops therapies against cancer and other life-threatening diseases by reprogramming endogenous protein quality control. Collaborations with […]
Read more
Collaborations
Boehringer Ingelheim collaborates with Proxygen
7 December 2020 —
Boehringer Ingelheim and Proxygen today announced they have entered into a collaboration and license agreement to enable the identification of molecular glue degraders against various oncogenic targets. The collaboration combines Proxygen’s unique molecular glue degrader discovery platform and its expertise in targeted protein degradation with Boehringer Ingelheim’s long-term strategy to provide first-in-class, breakthrough therapies for […]
Read more
